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mg relative to placebo. 
Conclusions In addition to reducing EDS and improving QOL for patients with OSA, 
modafinll does not wcrsen BP in patients with HTN. The lack of change in HR suggests 
that modafinil may decrease the sympathetic activation seen in HTN patients with OSA. 
Effects on BP and HR in HTN (* denotes sigmiicant change from baseline) 
HTN group Placebo 200mg 400mg 
Systolic BP baseline 130.8 * 12.6 131.5* 12.7 128.1 * 12.2 
Systolic BP change -2.1 * 12.3’ -3.4 * 15.3 1.8 *13.4 
Diastolic BP baseline 80.9 * 8.1 81.9 * 7.9 80.0 +7.6 
Diastolic BP change -2.2 r 8.8’ -3.9 * 9.1’ 0.9 * 9.2 
HR baseline 70.4 * 9.5 70.5*11.1 72.4 + 9.9 
HR change 0 * 9.6 -0.04 * 10.5 0.9 * 10.8 
1203-l 30 Relationship of Platelet P-Selectin Levels and Platelet 
Morphology to Platelet Activation in Hypertensives 
Sunil K. Nadar. Sridhar kamath, Andrew Blann, Gregory Y. Lip, City Hosptial, 
Birmingham, United Kingdom 
Background: Platelet activation occurs in hypertension. We undertook this study to eval- 
uate the relation of platelet levels of the adhesion molecule P-selectin to platelet activa- 
tion and platelet morphology in high risk hypertension. 
Methods: We studied platelet parameters from 199 consecutive patients with high risk 
hypertension and 59 age and sex matched normotenslve ccntrols. Platelet P-selectin in 
the three groups was measured by the lysate technique. 
Results: There was significant difference in platelet parameters in patients with hyperten- 
sion and normotensive controls ITablet]. Subgroup analysis of the hypertensive group 
showed that patients on aspirin had lower platelet [96.3 (57-130) x 10 * ng/platelet vs 
105.4 (84.143) x lo6 ng/platelet; p=O.O3] and soluble P-selectin[l35 (101-190) ng/plate- 
let vs 159.2 (118.5 -227) ngl platelet; p=O.Ol] than those who were not on aspirin. Other 
drugs such as calcium channel blockers and statins did not influence these parameters, 
nor did factors such as diabetes or smoking. 
Conclusions: Hypertensive patients have platelets that appear to be larger and heavier 
than platelets from normotensive healthy controls. The increase in P- selectin values per 
platelet could further represent a heightened state of activation, which IS reduced with 
aspirin. 
Table 1: 
Age 
Male/Female 
SBP 
DBP 
Mean platelet volume (fl) 
PDW- Platelet distribution 
width(%) 
Mean platelet concentration(g/dl) 
Mean platelet mass(pg) 
Soluble p-selectin (@ml) 
Platelet P-se&tin (xl0 -6 ng/ 
platelet) 
beta thromboglobulin (IUirnl) 
*- Median(interquartile range) 
All other figures are mean (S.D) 
Controls 
n=59 
68.4 (11.01) 
41/18 (69.4%/ 
30.6%) 
130(9.9) 
80.5(9) 
6.36 (0.9) 
46.4(5.6) 
29(2.3) 
1.76(0.17) 
77 (38-l 10)’ 
78.3 (47-120) * 
100 (57.282) * 
Hypeltensives P 
II=199 value 
67.9 (9.9) 0.7 
151148 (75.90~1 0.3 
24.1%) 
147(22) 0.001 
80.1(11) 0.9 
7.8 (3.03) 0.005 
55.1(8.4) co.001 
27.1(2.5) <O.OOl 
1.9(0.21) <O.OOl 
150(106.8-213)‘ c0.001 
99.6 (73.2-138.5) * 0.004 
306.6(210-354) * <O.col 
1203-131 Accelerated Coronary Artery Calcification in Mildly 
Reduced Renal Function of High-Risk Hypertensives: A 
Three-Year Prospective Observation 
Joseph Shemesh, Michael Bursztyn. Ehud Grossman, Michael Mqtro, Cardiac 
Rehabilitation Institute, Sheba Medical Center, Israel, Hadassah University Hospital, 
Mount Scopus, Jerusalem, Israel 
Background: Patients with end stage renal disease have accelerated coronary artery cal- 
cifications. However the effect of mild renal dysfunction has not been described. 
Methods: We examined the progression of coronary atherosclerosis as measured by 
dual-section spwal computed tomography using the total coronary artery calcium score 
as a quantitative measure of the burden of atherosclerosis. Of the 547 high-risk hyper- 
tensive patients participants of the prospective calcification study, a side arm of the inter- 
national INSIGHT study, 313 patients completed the 3 years follow-up. Subjects were 
studied upon entry (on placebo) and again after 3 years of treatment (nifedipine or thiaz- 
ide). Patients were divided to 2 groups depending on their creatinine clearance: zZiOml/ 
rnln renal dysfunction (RD) (n=53), and >GOmVmin-normal renal function group (11~263). 
Results: Blood pressure, hypercholesterolemia, and smoking did not differ between the 
groups. After 3 years of treatment blood pressure control was similar, whereas the total 
coronary artery calcium score progression was 2 fold greater in the RD than the normal 
group, 156i32 vs. 64&. respectively, p=O.O06. In a multiple logistic regression analysis 
the odds ratio (OR) for total coronary artery calcium score progression was higher for the 
RD group: 2.1 with 95%confidence interval (Cl) of 1.2-3.7. Gender, body mass index, 
smoking, cholesterol, family history of IHD, and diabetes were not significant predictors. 
Thiazide based antlhypertensive therapy predicted a faster progression compared to 
nifedipine, OR 1.66 95% Cl 1.09-2.51. 
Conclusion: Mild renal dysfunction accelerates coronary artery calcifications, above and 
beyond conventional risk factors. Nifedipine may have a protective role. 
1203-l 32 An Affected Pedigree Member Analysis of the Linkage 
Between the Taql Polymorphism of the Dopamine D2 
Receptor Gene and Obesity-Related Hypertension in 
Hong Kong Chinese 
Yu-Jina Fang G. Neil Thomas, i’ong-Li Xu, Ji-Qian Fang, Brian Tomlinson, Chinese 
University of Hong Kong. Shatin, Hong Kong, Sun Yat-Sen University of Medicine 
Science, Guangzhou, People’s Republic of China 
Background: Dopamine modulates a variety of physiological functions including natri- 
uresis and satiety. We have previously reported that the Taql polymorphism of the 
dopamine D2 receptor (DDPR) gene is associated with both blood pressure and obesity 
indices in a normoglycaemic Hong Kong Chinese population. In this study, we present 
evidence confirming the linkage between this gene polymorphism and obesity-related 
hypertension. 
Methods: Family members of 96 normoglycaemic hypertensive subjects were recruited, 
including 281 siblings, of which 133 were hypertensive. Central obesity was defined as a 
waist-to-hip ratio oft0.9 and20.85 in males and females respectively, and was identified 
in 98 of the siblings. The DDPR gene Taql polymorphism was identified with a poly- 
merase chain reaction based restriction fragment length polymorphism protocol. Affected 
pedigree member linkage analysis (sib-pair program, version 0.99.9, by DL Duffy) was 
used to assess for linkage between this gene polymorphism and obesity-related hyper- 
tension. 
Results: Linkage analysis was used to analyze 73 families with siblings discordant for 
hypertension. Based on the data of 133 hypertensive siblings, 69 central obese hyper- 
tensive siblings and 118 non-obese normotensive siblings, the Al allele frequencies 
were similar at 0.431, 0.426 and 0.429 respectively. Affected pedigree member linkage 
analysis suggested that the DDPR gene Taql polymorphism had significant linkage with 
blood pressure (t-1.86, p=O.O13) as well as obesity-related hypertension (t=-1.58. 
p=0.007). 
Conclusions: Our data in normoglycaemic Hong Kong Chinese supports that the DDPR 
gene Taql polymorphism is a marker associated with the pathogenesis of obesity-related 
hypertension. 
1203-133 Treatment Patterns and Goal Attainment Among 
Hypertensive Patients With and Without Dyslipidemia 
and/or Diabetes 
J. Sanford Schwartz. Trent McLaughlin, Deborah Griffis, Amy Arnold, Daniel Penitt, NDC 
Health, Phoenix, AZ, Pfizer. Inc., New York, NY 
Backgrounrt The purpose of this analysis was to determine treatment patterns among 
hypertenswe patients with either dyslipidemia (DL) or diabetes (DM) and assess the pro- 
portion that reach blood pressure goal versus those with hypertension (HTN) alone. 
Methods: Retrospective analysis using the GE Medical MQIC database. This database 
consists of electronic medical records collected from 8 primary care sites around the 
United States. Patients with a diagnosis and/or clinical evidence (defined as meeting 
JNC-VI hypertension or NCEP-ATPIII guidelines) were identified and followed throughout 
2001. Patients were stratified based on the presence of either DL or DM. Patients were 
further required to have received pharmacotherapy and have 21 recorded blood prss- 
sure tc determine goal status. Blood pressure goal was defined as meeting the goal set 
by JNC-VI or ADA, after accounting for patient risk factors. 
ResuItS: Of the 41,417 hypertensive patients included in the analysis, approximately 
47% also had DL and/or DM. As shown below, although patients with multiple conditions 
were mere likely to be receiving multiple antihypertensive drugs (AHDs) compared to 
patients with HTN alone, there were significantly less likely to achieve blood pressure 
goal. 
Conclusions Despite receiving mere antihypertensive medications, patients with multi- 
ple conditions were significantly less likely to achieve blood pressure goal during the 
study period. 
N At Blood Pressure Drug Classes 
Goal 
1 AHD 2AHDs 3+ AHDs 
HTN alone 21.807 37.2% 47.7% 27.2% 25.0% 
HTN+DL 12,687 30.2%’ 39.0% 28.7% 32.3% 
HTN+DM 2,261 30.2%’ 31.4% 25.7% 42.8% 
HTN+DL+DM 4,662 29.9%’ 29.3% 26.0% 44.7% 
‘~0.001 vers”s HTN alone 
AHD = Antihypertenswe drug 
